GRI Bio, Inc.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory, fibrotic, and autoimmune diseases driven by dysregulated immune responses. The company has no approved products yet and is focused on advancing product candidates such as GRI-0621 and GRI-0803 through preclinical and clinical development toward eventual commercialization.

3.25

— GRI Bio, Inc.
	%
Clinical-stage product candidates	0% Drug candidates in preclinical and clinical development, including GRI-0621 and GRI-0803.
Research and development programs	100% Discovery and development work aimed at immune-response targets for inflammatory and autoimmune disease.
Future commercial therapies	0% Potential marketed products if candidates receive regulatory approval and are launched.

GRI Bio does not yet sell commercial products, so its near-term 'customers' are primarily clinical trial participants,...

Clinical development partnersprimary
CROs, investigators, and trial sites that execute studies and generate data needed for regulatory advancement.
Regulatory agenciesprimary
FDA and other regulators that review safety, efficacy, and manufacturing data before approval.
Physicians and specialistssecondary
Potential future prescribers in immunology, pulmonology, hepatology, and related specialties.
Third-party payorssecondary
Commercial insurers and government programs that would influence adoption and reimbursement after approval.
Patients with immune-mediated diseasesecondary
End users of any approved therapy for inflammatory, fibrotic, or autoimmune disorders.

GRI Bio is headquartered in La Jolla, California and operates as a U.S.-based development-stage biotech company...

•Headquartered in La Jolla, California
•U.S.-based clinical development and corporate operations
•No disclosed country revenue mix because there is no product revenue
•Future geographic exposure depends on trial sites and approval markets
•Potential commercialization could expand beyond the U.S.

The company’s strategy is to advance GRI-0621, GRI-0803, and future candidates through clinical development, while...

Advance lead clinical programsshort-term

The company has no approved products, so value creation depends on generating human efficacy and safety data.

Secure additional fundingshort-term

Management disclosed substantial doubt about going concern and expects continued operating losses.

Build regulatory and manufacturing readinessmedium-term

Clinical-stage biotech must demonstrate quality, safety, and manufacturability before approval.

GRI Bio faces the core risks of a clinical-stage biotech: development failure, regulatory setbacks, and the need for...

critical

Clinical development failure

GRI-0621, GRI-0803, and other candidates must still prove safety and efficacy in trials.

Scope: Lead programs
Materiality: high

critical

Going concern / financing risk

The company expects continued losses and disclosed substantial doubt about its ability to continue as a going concern.

Scope: Corporate liquidity
Materiality: high

high

Regulatory approval risk

Drug candidates require IND clearance, clinical success, and marketing approval before commercialization.

Scope: FDA and other regulators
Materiality: high

high

Competition from larger biopharma companies

Competitors may have greater capital, broader pipelines, and faster development capabilities.

Scope: Target disease areas such as IPF and autoimmune disorders
Materiality: medium

medium

Cybersecurity and third-party operational risk

The company relies on CROs, clinical sites, and contractors that process sensitive data and run trials.

Scope: Research data and clinical operations
Materiality: medium

Accrued research and development costs

Can shift quarterly R&D expense and liabilities materially

Stock-based compensation

Affects operating loss and comparability across periods

Lease accounting

Impacts balance sheet leverage and occupancy expense timing

Going concern assessment

Important for interpreting financing risk and disclosure quality

GRI Bio, Inc.

Clinical development failure

Going concern / financing risk

Regulatory approval risk

Competition from larger biopharma companies

Cybersecurity and third-party operational risk

Pluri Inc.

GRAIL, Inc.

GridAI Technologies Corp.

Regenerative Medical Technology Group Inc.

CG Oncology, Inc.

PALISADE BIO, INC.